Literature DB >> 10790731

A unifying hypothesis for the renin-angiotensin system and hematopoiesis: sticking the pieces together with the JAK-STAT pathway.

I C Haznedaroğlu1, M Arici, Y Büyükaşik.   

Abstract

JAK-STAT pathway is a recently encountered intracellular signal transduction system. The pathway is utilized by numerous cytokines, growth factors, and hormones for gene expression and a variety of biological activities. Hematopoiesis is regulated by many cytokines and growth factors that support the proliferation and differentiation of progenitor cells in the bone marrow. JAK-STAT pathway arises as the most common signalling cascade of a wide range of cytokines and/or growth factors in propagation of physiological and pathological/neoplastic hematopoiesis. On the other side, renin-angiotensin system (RAS) includes not only the classic circulating endocrine system controlling blood pressure and electrolyte homeostasis, but also tissue-specific RASs with autocrine and/or paracrine functions. Preliminary data suggest the involvement of the RAS components in normal and pathologic hematopoiesis, although the precise mechanism of action has not been elucidated yet. We have hypothesized, in this report, that JAK-STAT pathway serves as a point of crosstalk between the components of the locally present RAS in the bone marrow and hematopoiesis. Demonstration of a local RAS in the bone marrow with clarification of the postreceptor signalling events may play a consequential role not only for further clarification of normal hematopoiesis but also novel therapeutic approaches in pathologic/neoplastic conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10790731     DOI: 10.1054/mehy.1998.0830

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  8 in total

1.  Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.

Authors:  Peng-Chieh Chen; Hiroko Wakimoto; David Conner; Toshiyuki Araki; Tao Yuan; Amy Roberts; Christine E Seidman; Roderick Bronson; Benjamin G Neel; Jonathan G Seidman; Raju Kucherlapati
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

2.  Post-transplant erythrocytosis refractory to ACE inhibitors and angiotensin receptor blockers.

Authors:  Prakash Vishnu; Yenny Moreno Vanegas; Hani M Wadei; Candido E Rivera
Journal:  BMJ Case Rep       Date:  2018-06-28

3.  Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia.

Authors:  Yavuz Beyazit; Salih Aksu; Ibrahim C Haznedaroglu; Murat Kekilli; Muge Misirlioglu; Serdar Tuncer; Jale Karakaya; Ebru Koca; Yahya Buyukasik; Nilgun Sayinalp; Hakan Goker
Journal:  J Natl Med Assoc       Date:  2007-01       Impact factor: 1.798

Review 4.  Protein Kinases in Hematological Disorders.

Authors:  Mufide Okay; Ibrahim C Haznedaroglu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Insights Into Vascular Anomalies, Cancer, and Fibroproliferative Conditions: The Role of Stem Cells and the Renin-Angiotensin System.

Authors:  Ethan J Kilmister; Swee T Tan
Journal:  Front Surg       Date:  2022-04-27

6.  Local bone marrow Renin-Angiotensin system and atherosclerosis.

Authors:  Yavuz Beyazit; Tugrul Purnak; Gulay Sain Guven; Ibrahim C Haznedaroglu
Journal:  Cardiol Res Pract       Date:  2010-12-22       Impact factor: 1.866

Review 7.  Pathobiological Interactions of Local Bone Marrow Renin-Angiotensin System and Central Nervous System in Systemic Arterial Hypertension.

Authors:  Rafiye Ciftciler; Ibrahim Celalettin Haznedaroglu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-07       Impact factor: 5.555

8.  Local Renin-Angiotensin system in normal hematopoietic and multiple myeloma-related progenitor cells.

Authors:  Burak Uz; Suzin Çatal Tatonyan; Müge Sayitoğlu; Yücel Erbilgin; Ozden Hatırnaz; Salih Aksu; Yahya Büyükaşık; Nilgün Sayınalp; Hakan Göker; Osman İ Ozcebe; Uğur Ozbek; Ibrahim C Haznedaroğlu
Journal:  Turk J Haematol       Date:  2014-06-10       Impact factor: 1.831

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.